Merit Medical Acquires DFINE, Inc.

SOUTH JORDAN, Utah, July 06, 2016 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has acquired DFINE, Inc. headquartered in San Jose, California, in a merger transaction through which DFINE has become a wholly-owned subsidiary…

Details

Commercial Launch of the Long SpineSTAR® Ablation Instrument

DFINE® Announces Commercial Launch of the Long SpineSTAR® Ablation Instrument for the Palliative Treatment of Metastatic Spine Tumors SpineSTAR’s extended working length provides spine specialists greater access and ability to precisely target metastatic spine tumors in order to offer patients rapid, sustained pain relief improving their quality of life.  San Jose, Calif. (PRWEB) December 15,…

Details

First Patients Enrolled in the STARRT Clinical Study

San Jose, Calif. January 23, 2015 — DFINE, Inc.,announced today that the first two patients have been enrolled in the STARRT Clinical Trial at Providence Sacred Heart Medical Center, Spokane WA. The multi-center trial is the first prospective study to evaluate the treatment of painful metastatic lesions with STAR Targeted Radiofrequency Ablation (t-RFA) and Radiofrequency Targeted Vertebral Augmentation (RF-TVA) prior to or following radiation therapy.

Details

Multi-Center Trial Shows Significant Pain Relief For Spine Cancer Patients Following Targeted Radiofrequency Ablation Treatment

SAN JOSE, Calif. – July 21, 2014 – DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced the publication of a multi-center study in the July/August issue of Pain Physician Journal, the official peer-reviewed publication of the American Society of Interventional Pain Physicians (ASIPP). The study followed patients at…

Details

First Commercial Cases with STAR System in Europe

DFINE ANNOUNCES FIRST COMMERCIAL CASES WITH STAR TUMOR ABLATION SYSTEM IN EUROPE San Jose, Calif. – October 9, 2013 – DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced the completion of the first European commercial cases with the STAR™ Tumor Ablation System for the palliative treatment of painful metastatic…

Details

CE Mark of Approval for STAR™ Tumor Ablation System

DFINE, INC. RECEIVES CE MARK APPROVAL FOR STAR™ TUMOR ABLATION SYSTEM European Launch at CIRSE Annual Congress SAN JOSE, Calif., Sept. 12, 2013 — DFINE, Inc., a fast-growing market leader in the treatment of spinal diseases, today announced it has received CE Mark approval for the STAR™ Tumor Ablation System for treatment of painful metastatic…

Details